BIOFRONTERA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.298 EUR | -12.87% |
|
-4.49% | -27.32% |
| 05-15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
| 04-30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 223.3 | 206.3 | 145.6 | 83.94 | 97.31 | 25.59 |
| Enterprise Value (EV) 1 | 217.5 | 218.1 | 153 | 80.33 | 92.43 | 23.65 |
| P/E ratio | -24.7 x | -27.9 x | -12.7 x | 2.18 x | -1.98 x | -40.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.6 x | 6.6 x | 4.8 x | 2.92 x | 3.78 x | 0.79 x |
| EV / Revenue | 10.3 x | 6.98 x | 5.04 x | 2.79 x | 3.59 x | 0.73 x |
| EV / EBITDA | -12.3 x | -10.2 x | -101 x | -5.15 x | 52 x | 4.74 x |
| EV / FCF | -23.4 x | -14.8 x | -83.8 x | 104 x | -12.1 x | -16.5 x |
| FCF Yield | -4.26% | -6.75% | -1.19% | 0.97% | -8.26% | -6.08% |
| Price to Book | 13.7 x | 20.7 x | 19.7 x | 1.45 x | 4.78 x | 1.28 x |
| Nbr of stocks (in thousands) | 2,123 | 2,136 | 2,274 | 2,701 | 3,038 | 3,038 |
| Reference price 2 | 105.2 | 96.60 | 64.05 | 31.08 | 32.03 | 8.421 |
| Announcement Date | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 | 30/04/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 21.11 | 31.26 | 30.35 | 28.79 | 25.74 | 32.25 |
| EBITDA 1 | -17.74 | -21.34 | -1.518 | -15.6 | 1.778 | 4.995 |
| EBIT 1 | -18.48 | -23.38 | -5.61 | -15.88 | 1.591 | 4.782 |
| Operating Margin | -87.54% | -74.77% | -18.49% | -55.17% | 6.18% | 14.83% |
| Earnings before Tax (EBT) 1 | -19.27 | -4.777 | -12.7 | 35.68 | -43.21 | -2.127 |
| Net income 1 | -8.878 | -7.358 | -13.02 | 38.32 | -44.17 | -0.369 |
| Net margin | -42.06% | -23.53% | -42.92% | 133.11% | -171.6% | -1.14% |
| EPS 2 | -4.267 | -3.458 | -5.048 | 14.28 | -16.17 | -0.2100 |
| Free Cash Flow 1 | -9.275 | -14.72 | -1.824 | 0.7758 | -7.63 | -1.438 |
| FCF margin | -43.94% | -47.07% | -6.01% | 2.69% | -29.65% | -4.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 2.02% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 | 30/04/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
|---|---|---|---|---|
| Net sales 1 | 5.379 | 10.31 | 6.566 | 8.51 |
| EBITDA | - | - | - | - |
| EBIT | -4.991 | -22.77 | 1.152 | - |
| Operating Margin | -92.79% | -220.74% | 17.54% | - |
| Earnings before Tax (EBT) 1 | -5.384 | 50.31 | -28.1 | -7.961 |
| Net income 1 | -5.8 | 52.99 | -28.1 | -8.645 |
| Net margin | -107.83% | 513.77% | -427.96% | -101.59% |
| EPS | -2.100 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 17/11/21 | 30/04/22 | 17/05/22 | 19/08/22 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 11.8 | 7.33 | - | - | - |
| Net Cash position 1 | 5.84 | - | - | 3.61 | 4.88 | 1.93 |
| Leverage (Debt/EBITDA) | - | -0.5523 x | -4.828 x | - | - | - |
| Free Cash Flow 1 | -9.27 | -14.7 | -1.82 | 0.78 | -7.63 | -1.44 |
| ROE (net income / shareholders' equity) | -90% | -55.9% | -150% | 104% | -113% | -1.83% |
| ROA (Net income/ Total Assets) | -39.2% | -30% | -6.11% | -14.9% | 1.82% | 9.42% |
| Assets 1 | 22.67 | 24.55 | 213.1 | -256.9 | -2,430 | -3.917 |
| Book Value Per Share 2 | 7.700 | 4.660 | 3.240 | 21.50 | 6.690 | 6.580 |
| Cash Flow per Share 2 | 9.150 | 5.210 | 7.280 | 2.560 | 2.100 | 1.010 |
| Capex 1 | 0.51 | 1.85 | 0.77 | 0.63 | 0.98 | 0.91 |
| Capex / Sales | 2.43% | 5.93% | 2.55% | 2.19% | 3.81% | 2.83% |
| Announcement Date | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 | 30/04/24 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- B8FK Stock
- B8F Stock
- Financials Biofrontera
